Abstract
Immune checkpoint inhibitors(ICIs) have been associated with the development of multiple cutaneous and/or extracutaneous immune-related adverse events(cirAEs/irAEs). Given the prevalence and morphologic diversity of cirAEs, multiple distinct toxicities are particularly common in the skin, but these patterns remain poorly characterized. We sought to examine associations among multiple cirAE status, cirAE features, and irAE risk in patients receiving ICIs. In this retrospective cohort study, we screened patients initiating ICI therapy at MGH (1/1/16-6/29/21) who developed cirAEs and abstracted clinical history.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
